Ionis Rare Disease Drug Is Headed to FDA, But Forthcoming Data Will Decide Competitive Profile
MedCity News
JANUARY 22, 2024
If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals. In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema.
Let's personalize your content